Cargando…
Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide.
A case-control study was conducted to determine whether the development of leukaemia was associated with chemotherapy for neoplasms of the ovary or breast, in a population where most such chemotherapy consisted of cyclophosphamide alone. Cases and controls were identified from the National Cancer Re...
Autores principales: | Haas, J. F., Kittelmann, B., Mehnert, W. H., Staneczek, W., Möhner, M., Kaldor, J. M., Day, N. E. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1987
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2002085/ https://www.ncbi.nlm.nih.gov/pubmed/3814491 |
Ejemplares similares
-
Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemia.
por: Tobias, J. S., et al.
Publicado: (1975) -
Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy.
por: van der Zee, A. G., et al.
Publicado: (1992) -
Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide.
por: Yuhas, J. M., et al.
Publicado: (1980) -
A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults.
por: Cuzick, J., et al.
Publicado: (1987) -
T‐cell modulation by cyclophosphamide for tumour therapy
por: Hughes, Ellyn, et al.
Publicado: (2018)